| Identification | Back Directory | [Name]
RUC-4 | [CAS]
1448313-27-6 | [Synonyms]
RUC-4
CPD1217
Zalunfiban
Acetamide, 2-amino-N-[5-[5-oxo-7-(1-piperazinyl)-5H-1,3,4-thiadiazolo[3,2-a]pyrimidin-2-yl]-3-pyridinyl]- | [Molecular Formula]
C16H18N8O2S | [MDL Number]
MFCD31624244 | [MOL File]
1448313-27-6.mol | [Molecular Weight]
386.43 |
| Hazard Information | Back Directory | [Uses]
Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI)[1]. | [in vivo]
Zalunfiban (1~3.86 mg/kg; s.c.; 24 hours) makes platelet aggregation performed[1].
Zalunfiban (1~3.86 mg/kg; i.m.; 4.5 hours) leads to the onset of high-grade inhibition of platelet aggregation within 15-30 minutes that lasted from ~2 to >4.5 hours in a dose dependent manner[1]. | Animal Model: | Cynomolgus Monkey | | Dosage: | 1~3.86 mg/kg (Pharmacokinetic Analysis) | | Administration: | S.c.; 24 hours | | Result: | Platelet aggregation was performed.
|
| [References]
[1] Vootukuri S, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2-3):65-74. DOI:10.1017/cts.2019.382 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|